Provided by Tiger Trade Technology Pte. Ltd.

Neurocrine Biosciences

156.57
+1.430.92%
Pre-market: 157.020.4500+0.29%06:19 EDT
Volume:895.20K
Turnover:140.62M
Market Cap:15.97B
PE:22.95
High:159.94
Open:154.38
Low:152.04
Close:155.14
52wk High:186.12
52wk Low:122.14
Shares:102.00M
Float Shares:100.00M
Volume Ratio:0.97
T/O Rate:0.90%
Dividend:- -
Dividend Rate:- -
EPS(TTM):6.82
EPS(LYR):4.67
ROE:22.09%
ROA:11.70%
PB:4.32
PE(LYR):33.53

Loading ...

Neurocrine Chief Commercial Officer Eric Benevich Disposes of 2,154 Common Shares Worth $333,428.94

Reuters
·
10 hours ago

Neurocrine Biosciences' Ingrezza, Crenessity to Drive H2 Ahead of 'Catalyst-Rich' 2027, RBC Says

MT Newswires Live
·
Sep 08

Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Guardant Health (GH) and Neurocrine (NBIX)

TIPRANKS
·
Sep 08

Neurocrine Price Target Raised to $253.00/Share from $249.00 by Citigroup

Dow Jones
·
Sep 04

Neurocrine price target raised to $253 from $249 at Citi

TIPRANKS
·
Sep 03

Neurocrine Biosciences, Inc. : Citigroup Raises Target Price to $253 from $249

THOMSON REUTERS
·
Sep 03

U.S. Research Roundup-Broadcom, Deere & Co, Snowflake

Reuters
·
Sep 03

Neurocrine Biosciences Executives to Speak at Wells Fargo Healthcare Conference

Reuters
·
Sep 03

Neurocrine Biosciences (NBIX) Cleared An FDA Milestone, Is It Trading At A Discount?

Simply Wall St.
·
Aug 29

How Investors May Respond To Neurocrine Biosciences (NBIX) Phase 4 INGREZZA Patient-Reported Benefit Data

Simply Wall St.
·
Aug 27

Nxera Pharma Says Neurocrine Wins FDA IND Clearance for Phase 2 Alzheimer’s Cognition Trial of NBI-1117567

Reuters
·
Aug 26

Nxera Pharma Co., Ltd.: Milestone Payment is Expected to be Recognised in Full as Revenue in Q3 Fy2026

THOMSON REUTERS
·
Aug 26

Nxera Pharma Co., Ltd.: Nxera Pharma's Partner Neurocrine Biosciences Receives Ind Acceptance from FDA for Phase 2 Study of Nbi-1117567 for Alzheimer's Cognition

THOMSON REUTERS
·
Aug 26

Nxera Pharma Co., Ltd.: Partner Neurocrine Biosciences Received Ind Acceptance from U.S. Food and Drug Administration (FDA) for a Phase 2 Study of Nbi-1117567 for Alzheimer's Cognition

THOMSON REUTERS
·
Aug 26

S&P 500 Futures up in Premarket Trading; Dick's Sporting Goods, Ameris Bancorp Lag

Dow Jones
·
Aug 25

Neurocrine Biosciences (NBIX) Stock Still Looks Like A Bargain Following Its 59% Run

Simply Wall St.
·
Aug 25

Neurocrine Biosciences (NBIX) Could Be 28% Undervalued On Fresh INGREZZA Data

Simply Wall St.
·
Aug 18

Rhythm Pharmaceuticals Appoints Manher “AJ” Joshi as Chief Medical Officer

Reuters
·
Aug 17

Neurocrine price target lowered to $182 from $196 at Morgan Stanley

TIPRANKS
·
Aug 17

Neurocrine Price Target Cut to $182.00/Share from $196.00 by Morgan Stanley

Dow Jones
·
Aug 13